首页> 外文期刊>The American Journal of Human Genetics >Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains
【24h】

Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains

机译:机械洞察的NMDA受体失调的GluN2A和GluN2B激动剂绑定域中的罕见变体。

获取原文
获取原文并翻译 | 示例
           

摘要

Epilepsy and intellectual disability are associated with rare variants in the GluN2A and GluN2B (encoded by GRIN2A and GRIN2B) subunits of the N-methyl-D-aspartate receptor (NMDAR), a ligand-gated ion channel with essential roles in brain development and function. By assessing genetic variation across GluN2 domains, we determined that the agonist binding domain, transmembrane domain, and the linker regions between these domains were particularly intolerant to functional variation. Notably, the agonist binding domain of GluN2B exhibited significantly more variation intolerance than that of GluN2A. To understand the ramifications of missense variation in the agonist binding domain, we investigated the mechanisms by which 25 rare variants in the GluN2A and GluN2B agonist binding domains dysregulated NMDAR activity. When introduced into recombinant human NMDARs, these rare variants identified in individuals with neurologic disease had complex, and sometimes opposing, consequences on agonist binding, channel gating, receptor biogenesis, and forward trafficking. Our approach combined quantitative assessments of these effects to estimate the overall impact on synaptic and non-synaptic NMDAR function. Interestingly, similar neurologic diseases were associated with both gain-and loss-of-function variants in the same gene. Most rare variants in GluN2A were associated with epilepsy, whereas GluN2B variants were associated with intellectual disability with or without seizures. Finally, discerning the mechanisms underlying NMDAR dysregulation by these rare variants allowed investigations of pharmacologic strategies to correct NMDAR function.
机译:癫痫和智力障碍与N-甲基-D-天冬氨酸受体(NMDAR)的GluN2A和GluN2B(由GRIN2A和GRIN2B编码)的亚基中的罕见变异有关,后者是在大脑发育和功能中起重要作用的配体门控离子通道。通过评估跨GluN2域的遗传变异,我们确定了激动剂结合域,跨膜域以及这些域之间的接头区域特别不耐受功能变异。值得注意的是,GluN2B的激动剂结合结构域表现出比GluN2A更大的变异耐受性。为了了解激动剂结合域中的错义变异的后果,我们研究了GluN2A和GluN2B激动剂结合域中25种稀有变体失调NMDAR活性的机制。当引入重组人NMDAR中时,在神经系统疾病患者中鉴定出的这些罕见变体对激动剂结合,通道门控,受体生物发生和正向运输具有复杂的,有时是相反的后果。我们的方法结合了对这些作用的定量评估,以评估对突触和非突触NMDAR功能的总体影响。有趣的是,相似的神经系统疾病与同一基因中功能获得和功能丧失的变异都有关。 GluN2A中最罕见的变异与癫痫有关,而GluN2B变异与有或没有癫痫发作的智力障碍有关。最后,通过这些罕见变体识别NMDAR失调的潜在机制,可以研究纠正NMDAR功能的药理策略。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号